NG2 antigen is a therapeutic target in human acute leukemia
Institute Josep Carreras
Filing date: 4 Aug, 2018
P14748PCT00
ICREA selecciona els investigadors únicament segons els seus mèrits científics. No obstant això, l'excel·lència científica porta sovint a la invenció de noves tecnologies i solucions. Quan passa això, ICREA fa costat a l'aprofitament d'aquestes oportunitats.
Els catedràtics de recerca de la ICREA treballen a diverses universitats i centres de recerca. Per això la titularitat de qualsevol propietat industrial es comparteix sempre entre la ICREA i la institució d'acollida. Perquè les negociacions siguin el més àgils i concloents possible, les institucions d'acollida tenen plena llibertat per emprendre activitats de transferència de tecnologia en nom d'ICREA, si en sorgeix l'oportunitat. ICREA recolza les accions encaminades a aquest aprofitament i presta assessorament al llarg de tot el procés.
Consulteu les nostres tecnologies actuals i contacteu amb ICREA per saber-ne més.
-
Life & Medical Sciences
NG2 antigen is a therapeutic target in human acute leukemia
Institute Josep Carreras
CLOSE -
Life & Medical Sciences
METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER
CLOSE METHODS FOR IMPROVING RESPONSE TO ANTI-LIF ANTIBODY TREATMENT IN INDIVIDUALS WITH CANCER
Filing date: 18 Jun, 2018
-
Life & Medical Sciences
METHODS OF QUANTIFYING LIF AND USES THEREOF
CLOSE METHODS OF QUANTIFYING LIF AND USES THEREOF
Filing date: 18 Jun, 2018
-
Life & Medical Sciences
COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC AGENTS FOR USE IN TREATING CANCER
CLOSE COMBINATION OF LIF INHIBITORS AND PLATINUM-BASED ANTINEOPLASTIC AGENTS FOR USE IN TREATING CANCER
Filing date: 18 Jun, 2018
-
Life & Medical Sciences
LIF DOSAGES
CLOSE LIF DOSAGES
Filing date: 14 May, 2018
-
Life & Medical Sciences
COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN TREATING CANCER
Mosaic Biomedicals, S.L.U., et al
CLOSE COMBINATION OF LIF INHIBITORS AND PD-1 AXIS INHIBITORS FOR USE IN TREATING CANCER
Mosaic Biomedicals, S.L.U., et al
Filing date: 12 Apr, 2018
18382248.5-1111
-
Experimental Sciences & Mathematics
Photocatalyst system and use thereof in a photocatalytic process
CLOSE Photocatalyst system and use thereof in a photocatalytic process
Filing date: 15 Nov, 2017
EP17382772
-
Engineering Sciences
ID0097-00 / Confidential
ICFO and ICREA
CLOSE ID0097-00 / Confidential
ICFO and ICREA
Filing date: 6 Nov, 2017
Licenced date: 24 Nov, 2017
PCT/ES2017/070734
-
Experimental Sciences & Mathematics
LAYERED ELECTROOSMOTIC STRUCTURE
Osmotex AG
CLOSE LAYERED ELECTROOSMOTIC STRUCTURE
A layered structure for pumping fluid by electroosmotic transport is provided. The layered structure comprising: a first layer, wherein the first layer is made from an ion perm selective material having openings therein that permit the fluid to flow therethrough, and wherein the openings in the first layer that permit the fluid to flow therethrough create a porosity of less than 10%; and a second layer, wherein the second layer is an electroosmotic layer. The layered structure having a net fluid flow direction that extends through the first layer and the second layer, wherein the layered structure has a region that permits fluid to flow in a direction that is non- parallel to a net fluid flow direction, and wherein the region is located between the first layer and the surface of the second layer that is furthest from the first layer. An electroosmodialysis apparatus may also be provided that comprises two layered structures.
Osmotex AG
Filing date: 8 Sep, 2017
WO/2018/046659
-
Life & Medical Sciences
Protein expression assays and methods
CRG
CLOSE Protein expression assays and methods
CRG
Filing date: 31 May, 2017
1708679.4
